Overview
- The White House Council of Economic Advisers report released Tuesday projects $529 billion in U.S. savings over 10 years from a policy that ties prices to those in other wealthy countries.
- The administration says 17 major manufacturers have signed voluntary agreements, yet key terms remain undisclosed as senators press legislation to force release of the contracts.
- For new medicines, companies would price U.S. launches in line with high‑income markets under a most‑favored‑nation model that pegs prices to overseas benchmarks.
- For existing drugs, the framework directs manufacturers to offer state Medicaid programs those benchmark prices, and the White House estimates $64.3 billion in combined federal and state savings.
- The plan faces skepticism, with a Sanders staff analysis reporting a 66% jump in profits at participating firms and a 2024 CBO warning that any price cuts could fade as companies adjust.